Abstract
This symposium aimed to address the current issues in the management of patients with Type 2 diabetes (T2D) post-acute coronary syndrome (ACS), bringing together the views of both cardiologists and diabetologists. T2D increases the risk of ACS and is associated with a poorer prognosis for these patients. Although guidelines provide comprehensive recommendations for patients with ACS, specific guidance is lacking following hospital discharge for those with concomitant T2D. As a result, these patients receive suboptimal treatment compared with patients without T2D. The cardiovascular (CV) benefits of intensive glucose lowering alone for those with T2D are uncertain. However, knowledge of the CV safety profiles of available therapies helps diabetologists to provide individualised treatment for their patients. Currently, three studies have reported on the CV safety of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with T2D. However, active inclusion of patients who are both post-ACS (15–90 days) and at high risk of CV disease (CVD) is rare. Only the DPP-4 alogliptin has been assessed in a CV safety outcome study in patients with this specific profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
